XPHETF

The State Street SPDR S&P Pharmaceuticals ETF (XPH) is reviewed as a reasonable option for investors seeking exposure to the pharmaceutical sector. With $459.89 million in assets, a low expense ratio of 0.35%, and strong year-to-date returns of 14.82%, the ETF offers diversified exposure across 64 pharmaceutical holdings.

However, it carries higher risk with a beta of 0.61 and standard deviation of 20.77%. Alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE) are also available for consideration.

The State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed fund offering broad exposure to the pharmaceutical sector with low costs (0.35% expense ratio) and solid year-to-date performance of 12.61%. However, the Healthcare-Pharma sector ranks 11th out of 16 Zacks sectors, and the ETF carries a 'Hold' rating with high risk (beta of 0.61, standard deviation of 20.68%). Investors may also consider alternative pharma ETFs like FTXH and IHE.